Literature DB >> 31173468

Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication.

Zobair M Younossi1,2, Maria Stepanova3, Issah Younossi3, George Papatheodoridis4, Harry L A Janssen5, Kosh Agarwal6, Mindie H Nguyen7, Ed Gane8, Naoky Tsai9, Fatema Nader3.   

Abstract

BACKGROUND & AIM: Chronic infections with hepatitis B or C (HBV and HCV) are associated with adverse clinical outcomes and patient-reported outcomes (PROs). The aim is to compare PRO scores in patients with chronic HBV and HCV without advanced liver disease before and after suppression/clearance of their infection.
METHODS: Patients with HCV and HBV infection prior to initiation of antiviral treatment and after viral suppression/eradication completed PRO questionnaires.
RESULTS: We included 132 patients with HBV and 132 matched patients with HCV. Baseline PRO scores were significantly higher in patients with HBV in the domains of Physical Functioning, Role Physical, Bodily Pain, Social Functioning, and Role Emotional of SF-36, SF-6D utility, Emotional and Fatigue domains of CLDQ, Presenteeism and total Work Productivity Impairment of WPAI:SHP in comparison to patients with HCV by 5.8%-13.2% of a PRO score range (all P < 0.05). After viral suppression (HBV DNA < 20 IU/mL after 48 weeks of treatment for HBV) or eradication (SVR-12 for HCV), only Physical Functioning and Role Physical scores remained higher in HBV by 6.7%-9.9%, while other PRO scores became similar between HBV and HCV groups (P > 0.05). The most prominent improvement of PROs in HCV was noted in Vitality, Emotional, Fatigue and Worry domains. In addition, General Health, Worry and Work Productivity scores were the most improved in HBV.
CONCLUSIONS: Prior to treatment, PRO scores were lower in patients with HCV in comparison to HBV. After successful treatment, both groups of patients experienced improvement in some PRO domains confirming the positive impact of treatment.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  activity; direct-acting antivirals; oral anti-viral therapy; quality of life; sofosbuvir; vesatolimod

Mesh:

Substances:

Year:  2019        PMID: 31173468     DOI: 10.1111/liv.14171

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  4 in total

1.  Assessing health-related quality of life and health utilities in patients with chronic hepatitis B-related diseases in China: a cross-sectional study.

Authors:  Meng Zhang; Yaoguang Li; Zihao Fan; Dongqi Shen; Xueying Huang; Qi Yu; Mei Liu; Feng Ren; Xiao Wang; Liping Dai; Peng Wang; Hua Ye; Jianxiang Shi; Xiaoang Yang; Shunxiang Zhang; Jianying Zhang
Journal:  BMJ Open       Date:  2021-09-15       Impact factor: 3.006

Review 2.  Flourish of Proton and Carbon Ion Radiotherapy in China.

Authors:  Yue Li; Xiaoman Li; Jiancheng Yang; Sicheng Wang; Meitang Tang; Jiawen Xia; Yunzhe Gao
Journal:  Front Oncol       Date:  2022-02-14       Impact factor: 6.244

3.  Chronic hepatitis D associated with worse patient-reported outcomes than chronic hepatitis B.

Authors:  Maria Buti; Maria Stepanova; Adriana Palom; Mar Riveiro-Barciela; Fatema Nader; Luisa Roade; Rafael Esteban; Zobair Younossi
Journal:  JHEP Rep       Date:  2021-03-17

Review 4.  The Lived Experience of Chronic Hepatitis B: A Broader View of Its Impacts and Why We Need a Cure.

Authors:  Thomas Tu; Joan M Block; Su Wang; Chari Cohen; Mark W Douglas
Journal:  Viruses       Date:  2020-05-07       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.